22.626 articles found

COMPOSITIONS AND METHOD FOR THE TREATMENT OF PARKINSON'S DISEASE

RODER HANNO.

· 2010-01-26

COMPOSITION AND METHOD FOR THE TREATMENT OF PARKINSON'S DISEASE

RODER HANNO.

· 2010-01-26

Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.

Ambrosi G, Armentero MT, Levandis G, Bramanti P, Nappi G, Blandini F.

Brain Res Bull · 2010-01-25

DOI: 10.1016/j.brainresbull.2010.01.011PMID: 20100549

Transcranial direct current stimulation in the treatment of anorexia.

Hecht D.

Med Hypotheses · 2010-01-21

DOI: 10.1016/j.mehy.2009.12.032PMID: 20096507

Extrapyramidal side effects and suicidal ideation under fluoxetine treatment: a case report.

Christodoulou C, Papadopoulou A, Rizos E, Tournikioti K, Gonda X, Douzenis A, Lykouras L.

Ann Gen Psychiatry · 2010-01-18

DOI: 10.1186/1744-859x-9-5PMID: 20148108

L-DOPA treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental model.

Ordoñez-Librado JL, Anaya-Martinez V, Gutierrez-Valdez AL, Montiel-Flores E, Corona DR, Martinez-Fong D, Avila-Costa MR.

Neurosci Lett · 2010-01-15

DOI: 10.1016/j.neulet.2010.01.015PMID: 20079802

Sirtuin 1 and the Treatment of Neurodegenerative Diseases

SNOW ALAN D, HU QUBAI, CAM JUDY A.

· 2010-01-12

MDR1 gene polymorphisms and response to acute risperidone treatment.

Kastelic M, Koprivsek J, Plesnicar BK, Serretti A, Mandelli L, Locatelli I, Grabnar I, Dolzan V.

Prog Neuropsychopharmacol Biol Psychiatry · 2010-01-11

DOI: 10.1016/j.pnpbp.2010.01.005PMID: 20060871

Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.

Lebel M, Chagniel L, Bureau G, Cyr M.

Neurobiol Dis · 2010-01-11

DOI: 10.1016/j.nbd.2009.12.027PMID: 20060905

Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging, disorders of aging, cancer, as growth factors, and as an alternative to stem cell therapy

RODRIGUEZ VICTORIO C.

· 2010-01-07

Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.

Lee SH, Kim MJ, Kim BJ, Kim SR, Chun S, Kim HK, Ryu JS, Kim GS, Lee MC, Chung SJ, Koh JM.

Calcif Tissue Int · 2010-01-05

DOI: 10.1007/s00223-009-9327-6PMID: 20049422

EXO-S-MECAMYLAMINE FORMULATION AND USE IN TREATMENT

SHYTLE DOUGLAS, SANBERG PAUL, NEWMAN MARY, SILVER ARCHIE A.

· 2010-01-04